Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00954681 · ClinicalTrials.gov registry record · Phase 2
Study of Quetiapine Treatment for Cannabis Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00954681 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 15 participants.
The verdict
NCT00954681, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients actively using cannabis 2. reduce cannabis intake and promote abstinence 3. treat the symptoms of cannabis withdrawal 4. reduce craving and relapse risk 5. have a low abuse liability.
Interventions
- DRUG quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00954681
The ClinicalTrials.gov registry entry for NCT00954681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quetiapine is the first listed.
NCT00954681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00954681 about?
NCT00954681 is a clinical study titled "Study of Quetiapine Treatment for Cannabis Dependence". Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administer...
What is the current status of trial NCT00954681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-08. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00954681?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00954681?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.